Compare Simon Property Group Inc (SPG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Simon Property Group Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Simon Property Group Inc trades at $200.01 (market cap $64.59B), while State Street SPDR S&P Biotech ETF trades at $154.13 (market cap $10.11B). The key difference: Simon Property Group Inc is far larger — about 6.4× State Street SPDR S&P Biotech ETF's market cap, and Simon Property Group Inc pays a 4.46% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Simon Property Group Inc for 99 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SPG | XBI | |
|---|---|---|
Market Cap | $64.59B | $10.11B |
Volume | 1,093,907 | 12,903,266 |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $236.70 | $169.55 |
52-Week Low | $173.35 | $104.99 |
Typical Hold Time | 99 Days | 38 Days |
Enterprise Value | $93.03B | — |
Dividend Yield | 4.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPG trades at $199.96, up 1.2% over the past day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with revenue of $6.36B and net income of $4.63B, though Q2 2026 earnings missed expectations. Analyst consensus is a $222.90 price target with 42% buy ratings. Recent news highlights strong leasing demand and a new media network launch, while rising bond yields pose a sector headwind.
SPG offers value with a P/E of 14.09 and robust profitability margins, but faces risks from high leverage with $24.21B in long-term debt and sensitivity to interest rates. The stock's current price below the consensus target suggests potential upside if operational strength continues, though investors should weigh debt maturities and economic cyclicality.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
